Clinical Trial Update: Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study investigating the combination of trastuzumab deruxtecan (DS-8201a) and olaparib in HER2-expressing cancers,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumor
• Ovarian Cancer High-grade Serous Carcinoma
• Unresectable Malignant Solid Tumor

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma | Phase 1 | Status: RECRUITING